Clinical Oncology
Volume 18, Issue 8 , Pages 600-607 , October 2006

Dose Escalation with Three-dimensional Conformal Radiotherapy for Prostate Cancer. Is More Dose Really Better in High-risk Patients Treated with Androgen Deprivation?

  • A. Zapatero

      Affiliations

    • Department of Radiation Oncology, Hospital Universitario de la Princesa, Madrid, Spain
    • Corresponding Author InformationAuthor for correspondence: A. Zapatero, Department of Radiation Oncology, Hospital Universitario de la Princesa, Diego de León 62, 28006 Madrid, Spain. Tel: +34-915202315.
    • ,
  • P. Ríos

      Affiliations

    • Department of Radiation Oncology, Hospital Universitario de la Princesa, Madrid, Spain
    • ,
  • A. Marín

      Affiliations

    • Department of Radiation Oncology, Hospital Universitario de la Princesa, Madrid, Spain
    • ,
  • R. Mínguez

      Affiliations

    • Department of Urology, Hospital Universitario de la Princesa, Madrid, Spain
    • ,
  • F. García-Vicente

      Affiliations

    • Department of Medical Physics, Hospital Universitario de la Princesa, Madrid, Spain

Received 18 May 2005 ,Revised 6 June 2006 ,Accepted 26 June 2006.

References 

  1. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–1105
  2. Zelefsky MJ, Leibel SA, Gaudin PB, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998;41:491–500
  3. Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001;166:876–881
  4. Fiveash JB, Hanks G, Roach M, et al. 3D conformal radiation therapy (3DCRT) for high grade prostate cancer: a multi-institutional review. Int J Radiat Oncol Biol Phys. 2000;47:335–342
  5. Vicini FA, Abner A, Baglan KL, Kestin LL, Martinez AA. Defining a dose–response relationship with radiotherapy for prostate cancer: is more really better?. Int J Radiat Oncol Biol Phys. 2001;51:1200–1208
  6. Hanks GE, Hanlon AL, Epstein B, Horwitz EM. Dose response in prostate cancer with 8–12 years' follow-up. Int J Radiat Oncol Biol Phys. 2002;54:427–435
  7. Zietman AL, DeSilvio M, Slater JD, et al. A randomized trial comparing conventional dose (70.2 GyE) and high-dose (79.2 GyE) conformal radiation in early stage adenocarcinoma of the prostate: results of an interim analysis of PROG 95-09. (Abstract) Int J Radiat Oncol Biol Phys. 2004;60:131
  8. Kupelian PA, Kuban D, Thames H, et al. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys. 2005;61:415–419
  9. Zietman AL, Nakfoor BM, Prince EA, Gerweck LE. The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: an in vitro and in vivo study. Cancer J Sci Am. 1997;3:31–36
  10. Joon DL, Hasegawa M, Sikes C, et al. Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys. 1997;38:1071–1077
  11. Pollack A, Salem N, Ashoori F, et al. Lack of prostate cancer radiosensitization by androgen deprivation. Int J Radiat Oncol Biol Phys. 2001;51:1002–1007
  12. Roach M, Lu J, Pilepich MV, et al. Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys. 2000;47:617–627
  13. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet. 2002;360:103–106
  14. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50:1243–1252
  15. Lawton CA, Winter K, Murray K, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;49:937–946
  16. Laverdiere J, Gomez JL, Cusan L, et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys. 1997;37:247–252
  17. Hanks GE, Pajak TF, Porter A, et al. Radiation Therapy Oncology Group phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003;21:3972–3978
  18. Zapatero A, Cruz-Conde A, Mínguez R, Rodríguez F, Pérez-Torrubia A. Control Bioquímico tras Radioterapia Externa en el Cáncer de Próstata Localizado: Resultados de una Cohorte Moderna. Actas Urol Esp. 2000;24:10–18
  19. Zapatero A, Garcia-Vicente F, Modolell I, et al. Impact of mean rectal dose on late rectal bleeding following conformal radiotherapy for prostate cancer: dose volume effect. Int J Radiat Oncol Biol Phys. 2004;59:1343–1351
  20. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;32:567–576
  21. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1035–1041
  22. Thames H, Kuban D, Levy L, et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys. 2003;57:929–943
  23. Cox DR. Regression models and life tables. J R Stat Soc (B). 1972;34:187–220
  24. D'Amico AV, Manola J, Loffredo M, et al. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. J Am Med Assoc. 2004;292:821–827
  25. Zapatero A, Valca´rcel F, Calvo FA, et al. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. J Clin Oncol. 2005;23:6561–6568
  26. Michalski JM, Winter K, Purdy JA, et al. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose level V. Int J Radiat Oncol Biol Phys. 2005;62:706–713
  27. Gardner BG, Zietman AL, Shipley WU, Skowronski UE, McManus P. Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. J Urol. 2002;167:123–126
  28. Peeters STH, Heemsbergen WD, Van Putten WLJ, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys. 2005;61:1019–1034

PII: S0936-6555(06)00224-X

doi: 10.1016/j.clon.2006.06.010

Clinical Oncology
Volume 18, Issue 8 , Pages 600-607 , October 2006

Article Tools

* Image Usage & Resolution